MedPath

A clinical trial to study the optimal dose of Hepatitis B vaccine in Human Immunodeficiency Virus (HIV) infected childre

Not Applicable
Conditions
Health Condition 1: null- Hepatitis B vaccination in HIV infected children
Registration Number
CTRI/2016/01/006495
Lead Sponsor
Shahid Akhtar Siddiqui
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Closed to Recruitment of Participants
Sex
Not specified
Target Recruitment
60
Inclusion Criteria

HIV infected children (diagnosed as per NACO guidelines)

HBsAg nonreactive

Exclusion Criteria

Received >=1 dose of Hepatitis B vaccine in past

Critically ill/moribund patients

Consent not given

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To compare the efficacy of standard dose vs. double dose of Hepatitis B vaccination in HIV infected ChildrenTimepoint: 12 weeks after complete vaccination
Secondary Outcome Measures
NameTimeMethod
To correlate seroprotection after Hepatitis B vaccination in HIV infected children with age, sex of patients, CD4 counts and HAART at vaccinationTimepoint: 12 weeks after complete vaccination
© Copyright 2025. All Rights Reserved by MedPath